This study highlights endothelial barrier protection by the SGLT2 inhibitor canagliflozin during sepsis, along with α1AMPK/p38MAPK/HSP27/VE-Cad pathway to play a key role in this effect. This evidence concerns the gene SLC5A2 and Sepsis.